Hong Binbin, Wen Yumei, Ying Tianlei
Key Laboratory of Medical Molecular Virology of Ministries of Education and Health, School of Basic Medical Sciences, Fudan University, Shanghai 200032, China.
Central Laboratory, the Second Affiliated Hospital of Fujian Medical University, Quanzhou 362000, China.
Infect Disord Drug Targets. 2019;19(3):213-223. doi: 10.2174/1871526518666180628122400.
Hepatitis B virus (HBV) infection remains a global health problem. As "cure" for chronic hepatitis B is of current priority, hepatitis B immunoglobulin (HBIG) has been utilized for several decades to provide post-exposure prophylaxis. In recent years, a number of monoclonal antibodies (mAbs) targeting HBV have been developed and demonstrated with high affinity, specificity, and neutralizing potency.
HBV neutralizing antibodies may play a potentially significant role in the search for an HBV cure. In this review, we will summarize the recent progress in developing HBV-neutralizing antibodies, describing their characteristics and potential clinical applications.
HBV neutralizing antibodies could be a promising alternative in the prevention and treatment of HBV infection. More importantly, global collaboration and coordinated approaches are thus needed to facilitate the development of novel therapies for HBV infection.
乙型肝炎病毒（HBV）感染仍然是一个全球性的健康问题。由于慢性乙型肝炎的“治愈”是当前的首要任务，乙肝免疫球蛋白（HBIG）已被使用数十年以提供暴露后预防。近年来，已经开发出多种靶向HBV的单克隆抗体（mAb），并显示出高亲和力、特异性和中和效力。
HBV中和抗体可能在寻找HBV治愈方法中发挥潜在的重要作用。在本综述中，我们将总结开发HBV中和抗体的最新进展，描述其特征和潜在的临床应用。
HBV中和抗体可能是预防和治疗HBV感染的一种有前途的替代方法。更重要的是，因此需要全球合作和协调方法来促进HBV感染新疗法的开发。
